Jubilant Organosys ties up with US-based Endo Pharmaceuticals

NEW DELHI: Jubilant Organosys through its Bangalore-based subsidiary Jubilant Biosys has entered into a three-year drug discovery & development
collaboration with US-based Endo Pharmaceuticals to come out with a portfolio of oncology molecules. The focus of the tie-up is to develop pre-clinical candidates for joint clinical development, a Jubilant Organosys release said. Endo will own the compounds developed under the partnership and will also be responsible for its worldwide commercialisation. Delhi-based Jubilant Organosys will receive research funding and success-based milestone payments from the American firm, besides royalties on successful commercialisation, the company statement added. Jubilant Organosys CMD Shyam Bhartia and Co-CMD Hari Bhartia in a joint statement said: “We anticipate significant rewards on successful development of compounds and its subsequent commercialisation.” While funding for research is expected to kick in from this quarter onwards, milestone linked payments for such research projects usually takes 6-9 months, subject to meeting the targets.